Magnetic Nanoparticle-Based High-Performance Positive and Negative Magnetic Resonance Imaging Contrast Agents
Pharmaceutics · 15.06.2023 · 15 (6) · 1745
DOI: 10.3390/pharmaceutics15061745 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 15.06.2023. Verfasst von Tirusew Tegafaw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Natural Sciences, Kyungpook National University, Taegu 41566, Republic of Korea. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korean government (Ministry of Science, and Information and Communications Technology: MSIT).
Abstract (Originalsprache)
In recent decades, magnetic nanoparticles (MNPs) have attracted considerable research interest as versatile substances for various biomedical applications, particularly as contrast agents in magnetic resonance imaging (MRI). Depending on their composition and particle size, most MNPs are either paramagnetic or superparamagnetic. The unique, advanced magnetic properties of MNPs, such as appreciable paramagnetic or strong superparamagnetic moments at room temperature, along with their large surface area, easy surface functionalization, and the ability to offer stronger contrast enhancements in MRI, make them superior to molecular MRI contrast agents. As a result, MNPs are promising candidates for various diagnostic and therapeutic applications. They can function as either positive (T1) or negative (T2) MRI contrast agents, producing brighter or darker MR images, respectively. In addition, they can function as dual-modal T1 and T2 MRI contrast agents, producing either brighter or darker MR images, depending on the operational mode. It is essential that the MNPs are grafted with hydrophilic and biocompatible ligands to maintain their nontoxicity and colloidal stability in aqueous media. The colloidal stability of MNPs is critical in order to achieve a high-performance MRI function. Most of the MNP-based MRI contrast agents reported in the literature are still in the developmental stage. With continuous progress being made in the detailed scientific research on them, their use in clinical settings may be realized in the future. In this study, we present an overview of the recent developments in the various types of MNP-based MRI contrast agents and their in vivo applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, College of Natural Sciences, Kyungpook National University, Taegu 41566, Republic of Korea.
- Department of Molecular Medicine, School of Medicine, Kyungpook National University, Taegu 41944, Republic of Korea.
ORCID-Profile: Tirusew Tegafaw, Mohammad Yaseen Ahmad, Abdullah Khamis Ali Al Saidi, Sung-Wook Nam, Gang Ho Lee
Förderung
- National Research Foundation of Korea
- Korean government (Ministry of Science, and Information and Communications Technology: MSIT)
Zitieren
APA
Tegafaw, T., Liu, S., Ahmad, M. Y., Saidi, A. K. A. A., Zhao, D., Liu, Y., Nam, S. W., Chang, Y., & Lee, G. H. (2023). Magnetic Nanoparticle-Based High-Performance Positive and Negative Magnetic Resonance Imaging Contrast Agents. Pharmaceutics, 15(6), 1745. https://doi.org/10.3390/pharmaceutics15061745
Vancouver
Tegafaw T, Liu S, Ahmad MY, Saidi AKAA, Zhao D, Liu Y, et al. Magnetic Nanoparticle-Based High-Performance Positive and Negative Magnetic Resonance Imaging Contrast Agents. Pharmaceutics. 2023;15(6):1745. doi:10.3390/pharmaceutics15061745
BibTeX
@article{Tegafaw2023,
author = {Tegafaw, Tirusew and Liu, Shuwen and Ahmad, Mohammad Yaseen and Saidi, Abdullah Khamis Ali Al and Zhao, Dejun and Liu, Ying and Nam, Sung-Wook and Chang, Yongmin and Lee, Gang Ho},
title = {Magnetic Nanoparticle-Based High-Performance Positive and Negative Magnetic Resonance Imaging Contrast Agents},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {6},
pages = {1745},
doi = {10.3390/pharmaceutics15061745}
}
EUVIMED